A Phase 3 interventional study of peginterferon alfa-2b (SCH 54031) in Chronic Hepatitis C and Cirrhosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2002, is one of 22 in phase 3, and was the 1st registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 631 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 99 across the 39 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 10th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2002, is one of 32 in phase 3, and was the 2nd registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
Biological: peginterferon alfa-2b (SCH 54031)
0.5 µg/kg subcutaneously once weekly for 60 months
Also known as: PegIntron
Time to Observation of the First Clinical Event Experienced by a Subject
Clinical events are liver decompensation \[variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites\], hepatic carcinoma, death, and/or liver transplantation
Time frame: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
Time to Observation of the Disease Progression Experienced by a Subject
Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.
Time frame: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
| Milestone | PegIntron | Untreated Control |
|---|---|---|
| Started | 311 | 315 |
| Completed | 195 | 197 |
| Not completed | 116 | 118 |
| Withdrew: Adverse event | 53 | 12 |
| Withdrew: Withdrawal by subject | 34 | 54 |
| Withdrew: Lost to follow-up | 5 | 5 |
| Withdrew: Protocol-defined clinical event | 17 | 32 |
| Withdrew: Noncompliance with protocol | 4 | 12 |
| Withdrew: Did not meet protocol eligibility | 2 | 2 |
| Withdrew: Administrative | 1 | 1 |
Clinical events are liver decompensation \[variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites\], hepatic carcinoma, death, and/or liver transplantation
| Participants | PegIntron | Untreated Control |
|---|---|---|
| <=6 Months | 3 | 2 |
| >6 to 12 Months | 5 | 5 |
| >12 to 18 Months | 4 | 4 |
| >18 to 24 Months | 3 | 7 |
| >24 to 30 Months | 7 | 6 |
| >30 to 36 Months | 1 | 6 |
| >36 to 42 Months | 0 | 5 |
| >42 to 48 Months | 2 | 0 |
| >48 to 54 Months | 2 | 1 |
| >54 to 60 Months | 0 | 0 |
| Total Over Study | 27 | 36 |
Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.
| Participants | PegIntron | Untreated Control |
|---|---|---|
| <=6 Months | 16 | 17 |
| >6 to 12 Months | 6 | 6 |
| >12 to 18 Months | 5 | 7 |
| >18 to 24 Months | 12 | 20 |
| >24 to 30 Months | 10 | 11 |
| >30 to 36 Months | 4 | 9 |
| >36 to 42 Months | 2 | 4 |
| >42 to 48 Months | 2 | 6 |
| >48 to 54 Months | 5 | 4 |
| >54 to 60 Months | 1 | 3 |
| Total Over Study | 63 | 87 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PegIntron | — | 93/311 (29.9%) | 290/311 (93.2%) |
| Untreated Control | — | 74/315 (23.5%) | 260/315 (82.5%) |
| Event | PegIntron | Untreated Control |
|---|---|---|
| HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/311 | 12/315 |
| OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders | 0/311 | 10/315 |
| ANAEMIABlood and lymphatic system disorders | 4/311 | 1/315 |
| CHOLELITHIASISHepatobiliary disorders | 4/311 | 0/315 |
| GASTROENTERITISInfections and infestations | 4/311 | 0/315 |
| PNEUMONIAInfections and infestations | 4/311 | 1/315 |
| VARICES OESOPHAGEALGastrointestinal disorders | 0/311 | 4/315 |
| CHOLECYSTITISHepatobiliary disorders | 3/311 | 3/315 |
| HEPATIC NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/311 | 2/315 |
| ALCOHOL ABUSEPsychiatric disorders | 3/311 | 1/315 |
| Event | PegIntron | Untreated Control |
|---|---|---|
| FATIGUEGeneral disorders | 103/311 | 78/315 |
| HEADACHENervous system disorders | 103/311 | 47/315 |
| MYALGIAMusculoskeletal and connective tissue disorders | 76/311 | 19/315 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 68/311 | 63/315 |
| SPLENOMEGALYBlood and lymphatic system disorders | 60/311 | 54/315 |
| PYREXIAGeneral disorders | 57/311 | 14/315 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 52/311 | 20/315 |
| VARICES OESOPHAGEALGastrointestinal disorders | 35/311 | 52/315 |
| HEPATOMEGALYHepatobiliary disorders | 45/311 | 51/315 |
| INSOMNIAPsychiatric disorders | 50/311 | 45/315 |
| Age, Customized(Participants) | PegIntron | Untreated Control | Total |
|---|---|---|---|
| <=50 years | 130 | 132 | 262 |
| >50 years | 181 | 183 | 364 |
| Sex: Female, Male(Participants) | PegIntron | Untreated Control | Total |
|---|---|---|---|
| Female | 105 | 100 | 205 |
| Male | 206 | 215 | 421 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Jun 2002, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b